Affordable Access

Promoter hypermethylation ofRASSF1AandRUNX3genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers

Authors
Journal
Lung Cancer
0169-5002
Publisher
Elsevier
Publication Date
Volume
58
Issue
1
Identifiers
DOI: 10.1016/j.lungcan.2007.05.011
Keywords
  • Hypermethylation
  • Non-Small Cell Lung Cancer
  • Prognosis
  • Rassf1A
  • Runx3
  • Histological Difference
Disciplines
  • Biology
  • Medicine

Abstract

Summary Aberrant methylation of promoter CpG islands is known to be a major inactivation mechanism of the tumor suppressor and tumor-related genes. Some published studies suggest a relationship to exist between the methylation status of several genes and the prognosis in non-small cell lung cancer (NSCLC); hypermethylation of the specific genes may be expected to serve as a biomarker for the prognosis, after a curative resection of NSCLC. To determine the relationship between the methylation status of the tumor suppressor and the tumor-related genes, and the clinicopathologic characteristics, including the survival rate, in patients with NSCLC after a surgical resection, we studied methylation in 10 genes ( DAPK, FHIT, H-cadherin, MGMT, p14, p16, RAR-β, RASSF1A, RUNX3, and TIMP-3) in 101 NSCLC cases by methylation-specific PCR (MSP). The methylation frequencies of the 10 genes examined in NSCLC were 26% for DAPK, 34% for FHIT, 26% for H-cadherin, 14% for MGMT, 8% for p14, 27% for p16, 38% for RAR-β, 42% for RASSF1A, 25% for RUNX3, and 12% for TIMP-3. Clinicopathologically, the patients with all stages of disease who had positive RASSF1A, RUNX3, or H-cadherin methylation status were found to have a significantly shorter duration of survival, as compared with the patients with a negative methylation status for those genes ( RASSF1A: P = 0.023, RUNX3: P = 0.035, H-cadherin: P = 0.039) in univariate analysis. Thereafter, while limiting our examination to patients with stage I disease, the patients who had a positive RASSF1A or RUNX3 methylation status were found to have a significantly shorter duration of survival, in comparison to the patients with negative methyaltion status for each of those genes ( RASSF1A: P = 0.022, RUNX3: P < 0.01) in univariate analysis. Next, the histological differences were recognized that the patients with RUNX3 methylation had a shorter duration of survival in adenocarcinomas (ACs) ( P = 0.045), in contrast to those with RASSF1A methylation who had a shorter duration of survival in squamous cell carcinomas (SCCs) ( P = 0.021). In multivariate analysis, both positive RASSF1A methylation status, and positive RUNX3 methylation status were found to be independent prognostic factors ( RASSF1A: P = 0.031, RUNX3: P = 0.028), as was TNM stage ( P = 0.004) and pleural involvement ( P = 0.037). In conclusion, the hypermethylation of RASSF1A or RUNX3 gene is therefore a useful biomarker to predict the prognosis in NSCLC, particularly RASSF1A due to SCCs and RUNX3 due to ACs.

There are no comments yet on this publication. Be the first to share your thoughts.